【Destiny Pharma-Product XF-73】Destiny Pharma Appoints Medpharm to Develop New XF-Platform Drug Formulations

Partner News

10th September
2019– Destiny Pharma
issued an announcement,
which is summarized as follows: 

Pharma announces it has been jointly awarded a National Biofilms Innovation
Centre (NBIC) grant to fund a research collaboration with the Sheffield Centre
for Antimicrobial Resistance and Biofilms at the University of Sheffield. The
project aims to establish the potential of two of the Company’s proprietary XF
drug compounds, DPD-207 and XF-73, as novel treatments for drug-resistant,
bacterial and fungal infections in a dynamic ex vivo eye model. NBIC’s stated
aim is to establish a network of research and innovation capacity catalysing
collaboration with industry in the study of biofilms to achieve breakthrough
and innovation. Financial terms of the collaboration have not been disclosed.

Original website Link: